Dr. DiNardo's research focus is on analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML. Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr. DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients.
MD Anderson Cancer Center: 1515 Holcombe Blvd, Houston, TX 77030, USA
Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Acute Myeloid Leukemia Newsletter" for Acute Myeloid Leukemia news, life
Acute Myeloid Leukemia stories, Acute Myeloid Leukemia clinical trials, Acute Myeloid Leukemia 101 articles and events with Acute Myeloid Leukemia
Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.